Literature DB >> 25751231

N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03.

Wenbo Wang1, Brett Zirkle, Jianhui Nie, Jian Ma, Kai Gao, Xiaojiang S Chen, Weijing Huang, Wei Kong, Youchun Wang.   

Abstract

BACKGROUND: HIV-1 gp120/gp41 is heavily modified by n-linked carbohydrates that play important roles either in correct folding or in shielding vulnerable viral protein surfaces from antibody recognition.
METHODS: In our previous work, 25 potential N-linked glycosylation sites (PNGS) of a CRF07_BC isolate of HIV-1 were individually mutated, and the resulting effects on infectivity and antibody-mediated neutralization were evaluated. To further understand the functional role of these PNGS, we generated double and multiple mutants from selected individual PNGS mutants. The effects were then evaluated by examining infectivity and sensitivity to antibody-mediated neutralization by neutralizing monoclonal antibodies (nMAbs) and serum antibodies from HIV-1 positive donors.
RESULTS: Infectivity results showed that, among the 12 combined PNGS mutants, only 197M.1 (N197D/N301Q) lost infectivity completely, whereas all others (except for 197M.6) showed reduced viral infectivity. In terms of neutralization sensitivity to known nMAbs, we found that adding N463Q mutation to all the gp120 mutants containing N197D significantly increased neutralization sensitivity to VRC01 and VRC03, suggesting N197 and N463 have a strong synergistic effect in regulating the neutralizing sensitivity of HIV-1 to the anti-CD4bs nMAbs VRC01/VRC03. Structural analysis based on the available structures of gp120 alone and in complex with CD4 and various nMAbs elucidates a molecular rationale for this experimental observation.
CONCLUSIONS: The data indicate that N463 plays an important role in regulating the CD4bs MAbs VRC01/VRC03 sensitivity in the genetic background of N197D mutation of gp120, which should provide valuable information for a better understanding of the interplay between HIV-1 and VRC01/03.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25751231      PMCID: PMC4506726          DOI: 10.1097/QAI.0000000000000595

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  45 in total

1.  Inference of macromolecular assemblies from crystalline state.

Authors:  Evgeny Krissinel; Kim Henrick
Journal:  J Mol Biol       Date:  2007-05-13       Impact factor: 5.469

2.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

3.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

4.  Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.

Authors:  Huihui Chong; Kunxue Hong; Chuntao Zhang; Jianhui Nie; Aijing Song; Wei Kong; Youchun Wang
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

5.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

6.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Authors:  Yuxing Li; Krisha Svehla; Mark K Louder; Diane Wycuff; Sanjay Phogat; Min Tang; Stephen A Migueles; Xueling Wu; Adhuna Phogat; George M Shaw; Mark Connors; James Hoxie; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

9.  Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Authors:  Piraporn Utachee; Shota Nakamura; Panasda Isarangkura-Na-Ayuthaya; Kenzo Tokunaga; Pathom Sawanpanyalert; Kazuyoshi Ikuta; Wattana Auwanit; Masanori Kameoka
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

10.  Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Authors:  Tongqing Zhou; Ling Xu; Barna Dey; Ann J Hessell; Donald Van Ryk; Shi-Hua Xiang; Xinzhen Yang; Mei-Yun Zhang; Michael B Zwick; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Joseph Sodroski; Richard Wyatt; Gary J Nabel; Peter D Kwong
Journal:  Nature       Date:  2007-02-15       Impact factor: 49.962

View more
  7 in total

1.  Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.

Authors:  Leopold Kong; Bin Ju; Yajing Chen; Linling He; Li Ren; Jiandong Liu; Kunxue Hong; Bin Su; Zheng Wang; Gabriel Ozorowski; Xiaolin Ji; Yuanzi Hua; Yanli Chen; Marc C Deller; Yanling Hao; Yi Feng; Fernando Garces; Richard Wilson; Kaifan Dai; Sijy O'Dell; Krisha McKee; John R Mascola; Andrew B Ward; Richard T Wyatt; Yuxing Li; Ian A Wilson; Jiang Zhu; Yiming Shao
Journal:  Immunity       Date:  2016-04-05       Impact factor: 31.745

Review 2.  Protein and Glycan Mimicry in HIV Vaccine Design.

Authors:  Gemma E Seabright; Katie J Doores; Dennis R Burton; Max Crispin
Journal:  J Mol Biol       Date:  2019-04-24       Impact factor: 5.469

3.  Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.

Authors:  Dai Zhang; Sen Zou; Yuanyuan Hu; Jiali Hou; Xintao Hu; Li Ren; Liying Ma; Xiang He; Yiming Shao; Kunxue Hong
Journal:  Front Microbiol       Date:  2019-05-24       Impact factor: 5.640

Review 4.  HIV-1 pseudoviruses constructed in China regulatory laboratory.

Authors:  Jianhui Nie; Weijin Huang; Qiang Liu; Youchun Wang
Journal:  Emerg Microbes Infect       Date:  2019-12-20       Impact factor: 7.163

5.  SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma.

Authors:  Emanuele Andreano; Giulia Piccini; Danilo Licastro; Lorenzo Casalino; Nicole V Johnson; Ida Paciello; Simeone Dal Monego; Elisa Pantano; Noemi Manganaro; Alessandro Manenti; Rachele Manna; Elisa Casa; Inesa Hyseni; Linda Benincasa; Emanuele Montomoli; Rommie E Amaro; Jason S McLellan; Rino Rappuoli
Journal:  bioRxiv       Date:  2020-12-28

6.  Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.

Authors:  Ananya Saha; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2020-11-30       Impact factor: 4.475

7.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.

Authors:  Qianqian Li; Jiajing Wu; Jianhui Nie; Li Zhang; Huan Hao; Shuo Liu; Chenyan Zhao; Qi Zhang; Huan Liu; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Linqi Zhang; Xuguang Li; Weijin Huang; Youchun Wang
Journal:  Cell       Date:  2020-07-17       Impact factor: 41.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.